Mifamurtide for the treatment of osteosarcoma

  • Technology appraisal guidance
  • TA235
  • Published: 
Download guidance (PDF)

1 Guidance

1.1 Mifamurtide in combination with postoperative multi-agent chemotherapy is recommended within its licensed indication as an option for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection in children, adolescents and young adults and when mifamurtide is made available at a reduced cost to the NHS under the patient access scheme.